Key facts
- This page summarizes Patrick D. Yeramian's Form 4 filing for Amylyx Pharmaceuticals, Inc. (AMLX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 11 Jan 2024, 17:04.
Patrick D. Yeramian - 09 Jan 2024 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- AMLX
- Reported as of
- 09 Jan 2024
- Net transaction value
- -$45,915
- SEC form
- 4
- Accepted by SEC
- 11 Jan 2024, 17:04:56 UTC
- Prior SEC filing
- 17 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joshua B. Cohen, as Attorney in Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Patrick D. Yeramian filed Form 4 for Amylyx Pharmaceuticals, Inc. (AMLX) on 11 Jan 2024.
Change
- Previous filing in this sequence was filed on 17 May 2023.
- Current net transaction value: -$45,915.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMLX
transaction
Common Stock
Sale
- Transaction value
- $45,915
- Shares
- -2,812
- Change %
- -1.3%
- Price
- $16.33
- Shares after
- 205,605
- Date
- 09 Jan 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
Footnote F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.18 to $16.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.